Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsBasile Njei, MD, PhD, MPH, FRCP, MD
Assistant Professor AdjunctAbout
Research
Publications
2026
Healthcare access and barriers in Jordan: Insights from a Nationwide Survey
Al-Ajlouni Y, Ayyad M, Tanashat M, Al Ta’ani O, AlMomani H, Nusier J, Abouzid M, Nagi Y, Njei B. Healthcare access and barriers in Jordan: Insights from a Nationwide Survey. PLOS ONE 2026, 21: e0345456. PMID: 41875192, PMCID: PMC13012521, DOI: 10.1371/journal.pone.0345456.Peer-Reviewed Original ResearchConceptsHealthcare accessSpecialist careBarriers to healthcare accessSelf-reported health statusAssociated with healthcare accessFear of diagnosisHealthcare access disparitiesHealth-related factorsMiddle-income countriesNationwide surveyHealth integrationPublic health concernChi-square testRoutine check-upHealth statusAccess disparitiesMarried participantsMarital statusEmployment statusExcellent healthSocioeconomic factorsHealthcareHealthcare infrastructureFinancial constraintsRetired individualsSemaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis
Njei B, Al-Ajlouni Y, Tanih D, Kanmounye U, Boateng S, Halwani K, Nguefang G, Lim J. Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis. Cost Effectiveness And Resource Allocation 2026 PMID: 41862906, DOI: 10.1186/s12962-026-00741-0.Peer-Reviewed Original ResearchStandard of careCases of hepatocellular carcinomaCases of decompensated cirrhosisClinical efficacy inputsLiver-related deathProbability of cost-effectivenessModerate to advanced fibrosisCardiovascular mortality benefitProbabilistic sensitivity analysesAdvanced fibrosisDecompensated cirrhosisHealthcare payer perspectiveHepatocellular carcinomaMortality benefitReceptor agonistsGlucagon-like peptide-1 receptor agonistsCost-effectiveness analysisPeptide-1 receptor agonistsPhase 3 trialF2-F3Simulate disease progressionPayer perspectiveResmetiromHypothetical cohortEconomic valueEpigenetic reprogramming in metabolic dysfunction–associated steatotic liver disease: from metabolic memory to precision medicine
Njei B, Al-Ajlouni Y. Epigenetic reprogramming in metabolic dysfunction–associated steatotic liver disease: from metabolic memory to precision medicine. Frontiers In Physiology 2026, 17: 1791638. DOI: 10.3389/fphys.2026.1791638.Peer-Reviewed Original ResearchSteatotic liver diseaseEpigenetic regulationEpigenetic reprogrammingDisease phenotypeDNA methylation signaturesLiver diseaseDevelopment of precision medicine approachesHistone modificationsDNA methylationChronic metabolic stressEpigenetic plasticityEpigenetic mechanismsMethylation signaturesEpigenetic alterationsConventional metabolic risk factorsHepatic gene expressionGene expressionBiological processesEpigenetic programmingMitochondrial dysfunctionMetabolic risk factorsChronic liver diseasePrecision medicine approachMetabolic stressPhysiological relevanceAI-Based Screening for At-Risk MASLD and Advanced Fibrosis in the US Population: A Cost-Effectiveness Analysis
Njei B, Tanih D, Al-Ajlouni Y, Boateng S, Nguefang G, Kanmounye U. AI-Based Screening for At-Risk MASLD and Advanced Fibrosis in the US Population: A Cost-Effectiveness Analysis. Digestive Diseases And Sciences 2026, 1-13. PMID: 41806252, DOI: 10.1007/s10620-026-09811-y.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioQuality-adjusted life yearsAdvanced fibrosisAt-risk adultsFIB-4Transient elastographyCost-effectiveness of screening strategiesUS payer perspectiveAI-based screeningRisk stratification toolAlternative screening strategiesCost-effectiveness ratioAt-riskStratification toolNo screeningSemaglutidePayer perspectiveLiver diseaseScreening programFibrosisSteatotic liver diseaseCost-effectiveCost-effectiveness analysisScreening strategiesResmetiromRacial and Gender Disparities in the Occurrence and Outcomes of Alcohol-Associated Hepatitis in Hospitalized Patients With Prior Bariatric Surgery
Boateng S, Gyabaah S, Issaka Y, Tchoukeu G, Ameyaw P, Ezeano C, Al-Ajlouni Y, Njei B. Racial and Gender Disparities in the Occurrence and Outcomes of Alcohol-Associated Hepatitis in Hospitalized Patients With Prior Bariatric Surgery. Cureus 2026, 18: e104251. PMID: 41909312, PMCID: PMC13030921, DOI: 10.7759/cureus.104251.Peer-Reviewed Original ResearchAlcohol-associated hepatitisHistory of bariatric surgeryIn-Hospital OutcomesBariatric surgeryIn-Hospital MortalityStatistically higher likelihoodHepatic decompensationImpact of bariatric surgeryAcute respiratory distress syndromePrior-bariatric surgeryAssociated with significantly lower oddsRespiratory distress syndromeAcute kidney injuryProtective effectPost-bariatric surgerySignificantly lower oddsNational Inpatient SampleCross-sectional studyPropensity score matchingDistress syndromeBaseline characteristicsKidney injurySubgroup analysisSurgeryWhite patientsArtificial intelligence agents in healthcare research: A scoping review
Njei B, Al-Ajlouni Y, Kanmounye U, Boateng S, Nguefang G, Njei N, Hamouri S, Al-Ajlouni A. Artificial intelligence agents in healthcare research: A scoping review. PLOS ONE 2026, 21: e0342182. PMID: 41666194, PMCID: PMC12890167, DOI: 10.1371/journal.pone.0342182.Peer-Reviewed Original ResearchConceptsArtificial intelligenceDecision support agentReal-world deploymentReal-time decision supportArtificial intelligent agentsIntelligent agentsAgent capabilitiesConversational agentsWorkflow automationAI systemsTransform healthcare deliveryAgent researchSimulation evaluationDecision supportEvaluation settingsSimulation environmentFunctional prototypeSupport agentsPRISMA-ScR guidelinesFull-text reviewScientific landscapeComplex decision-makingHealthcare ResearchEthical governance frameworkWeb of ScienceCannabis Use Disorder Is Associated With Increased Risk of Acute Myocardial Infarction in Adults With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis: A Population-Based Analysis
Njei B, Boateng S, Kwentoh I, Ameyaw P, Ezeani C, Nso N, Forsah S, Dimala C, Ugwendum D, Njei L, Al-Ajlouni Y, Lim J, Dranoff J. Cannabis Use Disorder Is Associated With Increased Risk of Acute Myocardial Infarction in Adults With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis: A Population-Based Analysis. Cureus 2026, 18: e103299. PMID: 41822655, PMCID: PMC12978627, DOI: 10.7759/cureus.103299.Peer-Reviewed Original ResearchCannabis use disorderIn-Hospital MortalityLength of stayInternational ClassificationHospitalized adultsAcute myocardial infarctionRisk of acute myocardial infarctionAdverse cardiovascular eventsAssociated with adverse cardiometabolic profilesRisk of acute MIAssociated with lower oddsAcute MICardiovascular eventsAdverse cardiometabolic profileObservational cross-sectional studyPoisson regression modelsRetrospective cross-sectional analysisHepatic decompensationMyocardial infarctionCross-sectional studyCross-sectional analysisHigh riskUse disorderPopulation-based analysisNational Inpatient SampleContraindications of steroid treatment in the setting of severe alcohol-associated hepatitis: are they absolute contraindications?
Altinbas A, Kreimeyer H, Basile N, Canbay A. Contraindications of steroid treatment in the setting of severe alcohol-associated hepatitis: are they absolute contraindications? Scand J Gastroenterol 2026, 61: 220-230. PMID: 41454791, DOI: 10.1080/00365521.2025.2608180.Peer-Reviewed Original ResearchInterpreting projected gastrointestinal cancer burden in Africa: The case of liver cancer
Njei B, Al-Ajlouni Y. Interpreting projected gastrointestinal cancer burden in Africa: The case of liver cancer. Cancer 2026, 132: e70296. PMID: 41626945, DOI: 10.1002/cncr.70296.Peer-Reviewed Original ResearchUsing Large Language Models to Predict Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Proof-of-Concept Analysis
Njei B, Njei N, Boateng S, Al Ta'ani O, Al-Ajlouni Y. Using Large Language Models to Predict Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Proof-of-Concept Analysis. Cureus 2026, 18: e102777. PMID: 41783890, PMCID: PMC12955738, DOI: 10.7759/cureus.102777.Peer-Reviewed Original ResearchNational Health and Nutrition Examination SurveyArea under the receiver operating characteristic curveTraditional risk scoresAdvanced liver fibrosisNAFLD fibrosis scoreHealth and Nutrition Examination SurveyRisk scoreNutrition Examination SurveyFIB-4Advanced fibrosisMetabolic risk factorsLiver fibrosisDetection of advanced fibrosisLiver diseaseSteatotic liver diseasePredicting advanced liver fibrosisAlanine aminotransferaseExamination SurveyFibrosis-4 indexReceiver operating characteristic curveType 2 diabetesAspartate aminotransferaseEffective clinical managementOperating characteristics curveProof-of-concept study
Academic Achievements & Community Involvement
News
News
- February 25, 2026
Njei to Visit Oxford via Sherlock Traveling Fellowship
- October 15, 2025
Welcome New Faculty and Postgrads in the Yale Department of Internal Medicine (October 2025)
- March 06, 2025
Meet Yale Internal Medicine: Basile Njei, MD, PhD, MPH
- December 03, 2024Source: MEDPAGETODAY
Lean MASH Patients Face Higher Mortality and Worse Outcomes
Get In Touch
Contacts
Email